Hybrid PET and MRI imaging on the horizon
First-ever study of the clinical use of new integrated PET/MRI technology shows promise for the detection of cancerous tumors
2011-06-07
(Press-News.org) San Antonio, Texas (June 6, 2011)—Preliminary research presented at SNM's 58th Annual Meeting is breaking new ground for the development of a brand new hybrid molecular imaging system. Simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) is providing important diagnostic information about soft tissues and physiological functions throughout the body. Scans focused on screening suspicious lesions for cancer are already comparable to more conventional molecular imaging methods. Further research could lead to the clinical use of PET/MRI as an additional tool for detecting cancer and other diseases.
"Combining MRI technology with PET in a single integrated system adds the advantages of the extremely broad spectrum of diagnostic MRI procedures to the arsenal of available PET procedures," said Alexander Drzezga, MD, TU Muenchen, Munich, Germany, lead author of the study. "This could potentially result in the development of new imaging agents that bring together specific diagnostic strengths of PET and MRI. It offers exciting scientific options to image physiologic and pathophysiologic processes at the same time and to improve our understanding of both. This and further studies could potentially open a whole new hybrid imaging discipline within the field of nuclear medicine."
The most commonly used hybrid molecular imaging technology is the PET/CT system. MRI shows some advantages for combination with PET when compared to computed tomography (CT), which uses X-ray technology to capture structural information but it is not as sensitive as MRI data in terms of soft tissue contrast. CT images of certain areas of the body—including the brain, head and neck, and pelvis—provide restricted resolution of anatomical structures. MRI technology is excellent for imaging these complex areas of soft tissue and may provide answers to unresolved musculoskeletal questions. In combination with PET, MRI may also have value for imaging liver and breast tissues and would provide a useful tool for imaging children due to its reduced radiation dose.
Simultaneous PET and MRI imaging has been a tricky business, as the magnetic field of MRI technology has limited PET imaging in the past, specifically the photomultipliers needed for data acquisition. Previous prototypes have been simply side-by-side designs or were solely for imaging the brain. The advent of "avalanche photodiodes" and their introduction to the new, fully integrated and whole-body PET/MRI prototype used in the current study is a leap forward for this technology. A number of these integrated scanners are available for research purposes worldwide. It is speculated that these systems will grow rapidly in number if clear clinical benefit continues to be demonstrated.
For this study, eleven patients with cancer diagnoses underwent dual-imaging single-injection PET/CT imaging followed by PET/MRI imaging. Simultaneous PET/MRI acquisition was feasible and offered good-quality PET and MRI diagnostic data. Tracer-uptake was similar in relation to lung, liver, spleen and bone scanning, all acquired within a short examination timeframe. Results already indicate that combined PET/MRI shows comparable performance in the detection, diagnosis and allocation of suspected tumors in patients with oncological diagnoses as compared to conventional PET/CT.
The next step for PET/MRI is studying the added benefit of introducing sophisticated MRI sequences to the diagnostic imaging protocol. This and other related studies may lead to the establishment of hybrid PET/MRI imaging as a new diagnostic imaging system similar to PET/CT for its effectiveness and ability to provide a wealth of both functional and anatomical information about the body.
INFORMATION:
Scientific Paper 262: A. Drzezga, M. Souvatzoglou, A. Beer, S. Ziegler, S. Fürst, S. Nekolla, M. Schwaiger, TU Muenchen, Munich, Germany; "Integrated simultaneous whole-body MR/PET: First comparison between MR/PET and PET/CT in patients," SNM's 58th Annual Meeting, June 4-8, 2011, San Antonio, TX.
END
ELSE PRESS RELEASES FROM THIS DATE:
2011-06-07
San Antonio, Texas (June 6, 2011)—A study presented at SNM's 58th Annual Meeting focuses on the effect that breathing irregularities have on the accuracy of 4D positron emission tomography (PET) scans and outlines a PET imaging method that reduces "motion artifacts" or image blurring arising from respiratory motion. Non-gated PET imaging with 4D computed tomography may be useful for imaging patients who do not benefit from the use of respiratory gating, most notably patients with erratic breathing.
"Breathing irregularities can lead to significantly underestimated lesion ...
2011-06-07
San Antonio, Texas (June 6, 2011)—Scientists presented new research at SNM's 58th Annual Meeting that has the potential to help physicians detect breast cancer by imaging the proliferation of blood vessels carrying oxygen and nutrients to breast tumors. Their study is evaluating a new imaging agent that is naturally drawn to angiogenesis—the development of new blood vessels in tissues both normal and cancerous. This process turns malignant during the growth stage of many cancerous tumors including those in breast tissue.
"The positive outcomes of this study are encouraging ...
2011-06-07
San Antonio, Texas (June 6, 2011)—A study introduced at SNM's 58th Annual Meeting may lead to the next wave of cancer imaging by helping to develop a molecular imaging agent that detects many malignant cancers' incessant development of blood vessels—a process called angiogenesis. A protein biomarker known as CD105 has been shown to indicate tumor angiogenesis in cancer patients.
"Non-invasive molecular imaging is a critical component of 21st century personalized medicine, and one of the hallmarks of cancer is angiogenesis," says Weibo Cai, PhD, assistant professor of ...
2011-06-07
San Antonio, Texas (June 6, 2011)—Definitive proof of an adverse effect of chronic marijuana use revealed at SNM's 58th Annual Meeting could lead to potential drug treatments and aid other research involved in cannabinoid receptors, a neurotransmission system receiving a lot of attention. Scientists used molecular imaging to visualize changes in the brains of heavy marijuana smokers versus non-smokers and found that abuse of the drug led to a decreased number of cannabinoid CB1 receptors, which are involved in not just pleasure, appetite and pain tolerance but a host of ...
2011-06-07
San Antonio, Texas (June 6, 2011)—Researchers the world over are advancing positron emission tomography (PET) as an effective method of early detection for Alzheimer's disease, a currently incurable and deadly neurological disorder. Three studies presented at SNM's 58th Annual Meeting are providing new insights into the development of Alzheimer's disease while opening the door to future clinical screening and treatments.
According to the World Health Organization, an estimated 18 million people worldwide are currently living with Alzheimer's disease—a number projected ...
2011-06-07
San Antonio, Texas (June 6, 2011)—A new study presented at SNM's 58th Annual Meeting could throw open the door to a recently established area of obesity research. Investigators have developed a novel molecular imaging agent that targets estrogenic mechanisms in the brain to find out what effect an enzyme called aromatase has on body mass index (BMI), a measurement of body fat based on height and weight. Aromatase is crucial for the production of estrogen in tissues throughout the body, including the brain.
According to the World Health Organization, worldwide obesity ...
2011-06-07
San Antonio, Texas (June 6, 2011)—Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. Patients with progressive kidney cancer receiving up to three doses of the therapy show dramatic slowing of cancer growth and stabilization of their disease.
"This study is another step forward in developing a cancer therapy that has the potential to provide additional treatment options for patients with renal cell carcinoma," says Wim Oyen, MD, professor and chairman of the department of nuclear ...
2011-06-07
San Antonio, Texas (June 6, 2011)—Research introduced at SNM's 58th Annual Meeting could be a sign of hope for patients with neuroendocrine cancer not responding well to standard therapies. Most radiotherapies use medical isotopes that emit beta radiation. The therapy in this study employs alpha particles, which have potential for higher potency. In fact, one single atom could be enough to kill an entire cancer cell.
"Until now, the usage of alpha radionuclides was limited to direct injection into the tumor or the use of only very small doses," says Clemens Kratochwil, ...
2011-06-07
San Antonio, Texas (June 6, 2011)—Investigators at SNM's 58th Annual Meeting are presenting results from a phase 1 clinical trial for a cancer therapy that has the potential to kill colorectal tumors with less destruction of healthy tissue. Further research could lead to the use of this radioimmunotherapy to eliminate residual cancer after surgery or as a standard treatment to keep tumors from returning or spreading to other organs.
"Compared to the conventional way of guiding radiation to tumors with radiolabeled antibody, pretargeted radioimmunotherapy offers an attractive ...
2011-06-07
San Antonio, Texas (June 6, 2011)—Research presented at SNM's 58th Annual Meeting is taking targeted molecular imaging to a new level by combining two commonly used imaging agents into one molecular imaging procedure. The combination of these agents creates a comprehensive examination of the extent of cancer spread within a variety of organ systems in the body.
"During a time when health care costs are under intense scrutiny, consolidated procedures such as this one that provide comprehensive imaging data are a benefit to everyone—to clinicians, healthcare administrators ...
LAST 30 PRESS RELEASES:
[Press-News.org] Hybrid PET and MRI imaging on the horizon
First-ever study of the clinical use of new integrated PET/MRI technology shows promise for the detection of cancerous tumors
